ClinicalTrials.gg
RecruitingNCT03392337Updated Jan 30, 2019

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

An interventional study of Narrowband UVB phototherapy in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.

Sponsored by Psoriasis Treatment Center of Central New Jersey · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2019, 6 years 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2017; still recruiting 9 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey — 5 open to participants now, 5 under way, none of them phase 3. Psoriasis · Psoriasis Treatment Center of Central New Jersey.

Planned enrollment
2nd of 12
30 · median 27
Started
2017
with 1 other
No phase
Only one
of the 13
Registered
5th of 13
by date

Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2017, is the only one with no phase, and was the 5th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, or all of them as a file.
02

Study summary

A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

Read the detailed description

30 subjects will be treated with increasing doses of Narrowband Ultraviolet phototherapy three times weekly for 12 weeks. Patients will then be evaluated every 6 weeks through week 36 to determine maintenance of response.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults ≥ 18 years of age.
  2. Diagnosis of chronic plaque-type psoriasis for at least 6 months
  3. Moderate to Severe plaque psoriasis as defined by BSA ≥10 PASI ≥12 IGA ≥3
  4. Able to give written prior to performance of any study related procedures
  5. Subject is able to attend Narrowband UVB phototherapy sessions three times a week and all other protocol specified visits
  6. Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic, and/or guttate psoriasis) or drug induced psoriasis
  2. History of photosensitivity
  3. Subject has used ustekinumab and/or anti-IL-17 biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose.
  4. Use of any drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
  5. Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral , methotrexate, acitretin, apremilast and cyclosporine).
  6. Patient used topical therapies to treat within 2 weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids, vitamin D analogs, or retinoids).
  7. Initiated within 3 months, planned initiation of, or changes to, concomitant medications that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors ) during the trial
  8. Active infections requiring antibiotics in the 2 weeks prior to Baseline
  9. Patient received UVB phototherapy within 4 weeks of Baseline.
  10. Patient received PUVA phototherapy within 4 weeks of Baseline.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Open Label Narrowband UVB phototherapy

    Open Label Narrowband UVB phototherapy for 12 weeks.

    Device: Narrowband UVB phototherapy

Interventions

  • DeviceNarrowband UVB phototherapy

    Ultraviolet B phototherapy

06

What researchers measure

Primary outcomes

  1. Psoriasis area severity index score

    PASI 75

    Time frame: 12 weeks

Secondary outcomes

  1. Physicians Global Assessment

    PGA improvement

    Time frame: 12 weeks

  2. Body Surface Area

    BSA improvement

    Time frame: 12 weeks

  3. Physician's Global Assessments multiplied by Body surface area

    PGA x BSA

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Elise Nelson
    East Windsor, New Jersey 08520, United States
    Recruiting
    • Jerry Bagel · Contactdreamacres1@aol.com · 609-443-4500
    • Elise Nelson · Contact6094434500
    • Jerry Bagel, MD · Principal investigator
    • Brian R Keegan, MD, PhD · Sub investigator
    • David S Nieves, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Dec 2019, 24 months after the start.

Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is above that.

Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2017
First posted
Jan 5, 2018
StartActual
Nov 7, 2017
Primary completionEst.
Dec 1, 2019
CompletionEst.
Jan 1, 2020
Last update
Jan 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03392337
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Responsible party
Sponsor
First posted
Jan 5, 2018
Start date
Nov 7, 2017
Primary completion
Dec 1, 2019 (estimated)
Completion
Jan 1, 2020 (estimated)
Last update
Jan 30, 2019

Study contacts

Jerry Bagel, MD
Contact
dreamacres1@aol.com
6094434500
Elise Nelson
Contact
enelson@windsordermatology.com
6094434500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion